|Articles|June 1, 2005
Santen CEO joins OccuLogix board
Napa, CA—Santen Inc.'s president and chief executive officer, Adrienne L. Graves, PhD, has joined the OccuLogix Inc. board of directors.
Advertisement
Before she became president in 2002, Dr. Graves was vice president of clinical affairs for Santen and helped to move three ophthalmic products through the FDA approval process. Prior to her work with Santen, Dr. Graves worked for Alcon Laboratories Inc.
Elias Vamvakas, OccuLogix's chairman and chief executive officer, said the company would benefit from Dr. Graves' involvement in the clinical, regulatory, and commercial development of the RHEO procedure.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Metformin use associated with reduced incidence of intermediate AMD
2
MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
3
Looking back at the 2025 EnVision Summit
4
Last year in glaucoma at EnVision Summit 2025
5
























